However, these findings lack validation in surgical cohorts.In post-CABG patients, initiation should be delayed until patients arehemodynamically stable, renal function is preserved, and oral intake is adequate.Therapy selection should reflect comorbidity profiles: SGLT2 inhibitors arepreferred for those with HFrEF or CKD. Here, SLC5A2 is linked to chronic kidney disease.